Document:

Exhibit 10.5

 

 [●], 2021

 

Schultze Special
Purpose Acquisition Corp. II

800 Westchester
Avenue, Suite S-632

Rye Brook,
NY 10573

 

Ladies and Gentlemen:

 

Schultze Special Purpose Acquisition
Corp. II (the “Company”), a blank check company formed for the purpose of entering into a merger, capital stock exchange,
asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses
or entities (a “Business Combination”), intends to register its securities under the Securities Act of 1933, as amended (“Securities
Act”), in connection with its initial public offering (“IPO”). The Company currently anticipates selling units (“Units”)
in the IPO, each comprised of one share of Class A common stock, par value $0.0001 per share, of the Company (“Common Stock”)
and one-third of one redeemable warrant (“Warrant”), each whole Warrant to purchase one share of Common Stock.

 

The undersigned hereby commits
to purchase an aggregate of 400,000 warrants of the Company (“Initial Private Placement Warrants”) at $1.50 per Initial Private
Placement Warrant for an aggregate purchase price of $600,000 (the “Initial Purchase Price”). Additionally, if the underwriters
in the IPO (“Underwriters”) exercise their over-allotment option in full or part, the undersigned further commits to purchase
up to an additional 60,000 warrants (“Additional Private Placement Warrants” and together with the Initial Private Placement
Warrants, the “Private Placement Warrants”) at $1.50 per Additional Private Placement Warrant, for an aggregate purchase price
of up to $90,000 (the “Over-Allotment Purchase Price”). The Private Placement Warrants will be identical to the Warrants underlying
the Units except as described in the Company’s registration statement on Form S-1 (File No. 333-254018) filed in connection with
the IPO (“Registration Statement”) and set forth below.

 

On the date of the closing
of the IPO (the “IPO Closing Date”), the Company shall issue and sell to the undersigned, and the undersigned shall purchase
from the Company, the Initial Private Placement Warrants for the Initial Purchase Price. On or prior to the IPO Closing Date, the undersigned
will cause the Initial Purchase Price to be delivered by wire transfer of immediately available funds to the accounts designated by the
Company, including to the trust account at a financial institution to be chosen by the Company, maintained by Continental Stock Transfer
& Trust Company, acting as trustee (the “Trust Account”), in accordance with the Company’s wiring instructions.
On the IPO Closing Date, subject to receipt of funds pursuant to the immediately prior sentence, the Company shall effect delivery of
the Initial Private Placement Warrants to the undersigned in book-entry form.

 

On the date of the closing
of the over-allotment option, if any, in connection with the IPO (each such date, an “Over-Allotment Closing Date,” and each
Over-Allotment Closing Date (if any) and the IPO Closing Date, a “Closing Date”), the Company shall issue and sell to the
undersigned, and the undersigned shall purchase from the Company, the Additional Private Placement Warrants (or, to the extent the over-allotment
option is not exercised in full, a lesser number of Additional Private Placement Warrants in proportion to the portion of the over-allotment
option that is exercised). On or prior to the applicable Over-Allotment Closing Date, the undersigned will cause the Over-Allotment Purchase
Price to be delivered by wire transfer of immediately available funds to the accounts designated by the Company, including to the Trust
Account, in accordance with the Company’s wiring instructions. On each Over-Allotment Closing Date, if any, subject to receipt of
funds pursuant to the immediately prior sentence, the Company shall effect delivery of the Additional Private Placement Warrants to the
undersigned in book-entry form.

 

The Private Placement Warrants
will be identical to the Warrants underlying the Units, except that:

 

		●	the Private Placement Warrants held by the undersigned
will not be exercisable more than five years from the commencement of sales of the IPO in accordance with FINRA Rule 5110(g)(8)(A);

 

     

     

    

 

		●	the Private Placement Warrants and the underlying
securities (collectively, the “Securities”) will not be transferable by the undersigned until 30 days after the consummation
of a Business Combination (subject to certain exceptions as described in the Registration Statement and set forth in the warrant agreement
governing the Private Placement Warrants (the “Warrant Agreement”));

 

		●	the Securities will be subject to customary registration
rights, pursuant to a registration rights agreement on terms agreed upon by the Company and the Underwriters to be filed as an exhibit
to the Registration Statement (the “Registration Rights Agreement”); and

 

		●	the Securities will include any additional terms
or restrictions as is customary in other similarly structured blank check company offerings or as may be reasonably required by the Underwriters
in order to consummate the IPO, which terms or restrictions will be described in the Registration Statement.

 

The undersigned acknowledges
and agrees that it will execute agreements in form and substance typical for transactions of this nature necessary to effectuate the foregoing
agreements and obligations prior to the consummation of the IPO as are reasonably acceptable to the undersigned, including but not limited
to (i) an insider letter and (ii) the Registration Rights Agreement. Additionally, the undersigned acknowledges that the Securities will
be deemed compensation by the Financial Industry Regulatory Authority (“FINRA”) and will therefore be subject to lock-up for
a period of 180 days from the commencement of sales of the IPO, subject to certain limited exceptions, pursuant to Rule 5110(e)(1) of
the FINRA Manual. Accordingly, the Securities may not be sold, transferred, assigned, pledged or hypothecated for 180 days from the commencement
of sales of the IPO except to any underwriter or selected dealer participating in the IPO and the bona fide officers or partners of the
undersigned and any such participating underwriter or selected dealer nor may they be the subject of any hedging, short sale, derivative,
put or call transaction that would result in the economic disposition of the securities by any person during such 180-day period.

 

The undersigned hereby represents
and warrants to the Company (which representations and warranties shall survive each Closing Date) that:

 

		(a)	it has been advised that the Securities have not been registered under the Securities Act;

 

		(b)	it is acquiring the Securities for its own account, for investment purposes only and not with a view towards,
or for resale in connection with, any public sale or distribution thereof;

 

		(c)	it understands that the Securities are being offered and will be sold to it in reliance on specific exemptions
from the registration requirements of the United States federal and state securities laws and that the Company is relying upon the truth
and accuracy of, and the undersigned’s compliance with, the representations and warranties of the undersigned set forth herein in
order to determine the availability of such exemptions and the eligibility of the undersigned to acquire such Securities;

 

		(d)	it is an “accredited investor” as defined by Rule 501(a)(3) of Regulation D promulgated under
the Securities Act, and it has not experienced a disqualifying event as enumerated pursuant to Rule 506(d) of Regulation D under the Securities
Act. The undersigned did not decide to enter into this letter agreement as a result of any general solicitation or general advertising
within the meaning of Rule 502(c) of Regulation D under the Securities Act;

 

		(e)	it has been furnished with all materials relating to the business, finances and operations of the Company
and materials relating to the offer and sale of the Securities which have been requested by the undersigned. The undersigned has been
afforded the opportunity to ask questions of the executive officers and directors of the Company. The undersigned understands that its
investment in the Securities involves a high degree of risk and it has sought such accounting, legal and tax advice as it has considered
necessary to make an informed investment decision with respect to the acquisition of the Securities;

 

		(f)	it understands that no United States federal or state agency or any other government or governmental agency
has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities
by the undersigned nor have such authorities passed upon or endorsed the merits of the offering of the Securities;

 

    2

     

    

 

		(g)	it understands that: (A) the Securities have not been and are not being registered under the Securities
Act or any state securities laws, and may not be offered for sale, sold, assigned or transferred unless (1) subsequently registered thereunder
or (2) sold in reliance on an exemption therefrom; and (B) except as specifically set forth in the Registration Rights Agreement, neither
the Company nor any other person is under any obligation to register the Securities under the Securities Act or any state securities laws
or to comply with the terms and conditions of any exemption thereunder. In this regard, the undersigned understands that the U.S. Securities
and Exchange Commission has taken the position that promoters or affiliates of a blank check company and their transferees, both before
and after an initial Business Combination, are deemed to be “underwriters” under the Securities Act when reselling the securities
of a blank check company. Based on that position, Rule 144 adopted pursuant to the Securities Act would not be available for resale transactions
of the Securities despite technical compliance with the requirements of such Rule, and the Securities can be resold only through a registered
offering or in reliance upon another exemption from the registration requirements of the Securities Act;

 

		(h)	it has such knowledge and experience in financial and business matters, knowledge of the high degree of
risk associated with investments in the securities of companies in the development stage such as the Company, is capable of evaluating
the merits and risks of an investment in the Securities and is able to bear the economic risk of an investment in the Securities in the
amount contemplated hereunder for an indefinite period of time. The undersigned has adequate means of providing for its current financial
needs and contingencies and will have no current or anticipated future needs for liquidity which would be jeopardized by the investment
in the Securities. The undersigned can afford a complete loss of its investments in the Securities;

 

		(i)	it understands that the Private Placement Warrants shall bear the legend substantially in the form set
forth in the Warrant Agreement and be subject to appropriate “stop transfer restrictions”;

 

		(j)	it has full power, authority and legal capacity to execute and deliver this letter agreement and any documents
contemplated herein or needed to consummate the transactions contemplated in this letter agreement;

 

		(k)	this letter agreement constitutes a legal, valid and binding obligation of the undersigned, enforceable
in accordance with its terms, subject to bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other laws of general
applicability relating to or affecting creditors’ rights and to general equitable principles (whether considered in a proceeding
in equity or law); and

 

		(l)	the execution and delivery by the undersigned of this letter agreement and the fulfillment of and compliance
with the terms hereof by the undersigned do not and shall not as of each Closing Date (a) conflict with or result in a breach by the undersigned
of the terms, conditions or provisions of, (b) constitute a default under, (c) result in the creation of any lien, security interest,
charge or encumbrance upon the undersigned’s equity or assets under, (d) result in a violation of, or (e) require any authorization,
consent, approval, exemption or other action by or notice or declaration to, or filing with, any court or administrative or governmental
body or agency pursuant to the undersigned’s organizational documents in effect on the date hereof or as may be amended prior to
completion of the contemplated IPO, or any material law, statute, rule or regulation to which the undersigned is subject, or any agreement,
instrument, order, judgment or decree to which the undersigned is subject, except for any filings required after the date hereof under
federal or state securities laws.

 

    3

     

    

 

All of the representations
and warranties contained herein shall survive each Closing Date. Except as otherwise expressly provided herein, all covenants and agreements
contained in this letter agreement by or on behalf of any of the parties hereto shall bind and inure to the benefit of the respective
successors of the parties hereto whether so expressed or not. Notwithstanding the foregoing or anything to the contrary herein, the parties
may not assign this letter agreement, other than assignments by the undersigned to affiliates thereof (including, without limitation one
or more of its members). This letter agreement may not be amended, modified or waived as to any particular provision, except by a written
instrument executed by the parties hereto.

 

Whenever possible, each provision
of letter agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this
letter agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of
such prohibition or invalidity, without invalidating the remainder of this letter agreement. This letter agreement may be executed simultaneously
in two or more counterparts, none of which need contain the signatures of more than one party, but all such counterparts taken together
shall constitute one and the same agreement.

 

Any notice, consent or request
to be given in connection with any of the terms or provisions of this letter agreement shall be in writing and shall be sent by express
mail or similar private courier service, by certified mail (return receipt requested), by hand delivery or electronic transmission.

 

This letter agreement shall
be deemed to be a contract made under the laws of the State of New York and for all purposes shall be construed in accordance with the
internal laws of the State of New York, without giving effect to conflicts of law principles that would result in the application of the
laws of another jurisdiction.

 

This letter agreement may
be terminated by the Company or the undersigned at any time after [●], 2021 upon written notice to the other party hereto if the
closing of the IPO does not occur prior to such date.

 

[Signature Page Follows]

 

    4

     

    

 

	 	Very truly yours,
	 	 
	 	STIFEL venture corp.
	 	 
	 	By:	 
	 	 	Name:  
	 	 	Title:    

 

	Accepted and Agreed:	 
	 	 
	Schultze Special Purpose Acquisition Corp. II	 
	 	 
	By:	 	 
	 	Name:  	George J. Schultze	 
	 	Title:	Chief Executive Officer	 

 

 

 

[Signature Page to Warrant
Purchase Agreement]Exhibit 4.5

       

      DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

       

      References to “ROCH” and the “Company” herein are, unless the context otherwise indicates, only to Roth CH Acquisition I Co. and not to any of its subsidiaries. As of December 31, 2020, the end of the period covered
        by this Annual Report on Form 10-K, ROCH has three classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Company’s common stock, $0.0001 par value (“common stock”), warrants
        to purchase common stock (“warrants”) and units comprised of one share of common stock and three-quarters of a warrant.

       

      The following description of the Company’s capital stock and provisions of the Company’s amended and restated certificate of incorporation, bylaws and the Delaware General Corporation Law are summaries and are
        qualified in their entirety by reference to the Company’s amended and restated certificate of incorporation and bylaws. Copies of these documents have been filed with the SEC as exhibits to the Annual Report on Form 10-K to which this description
        has been filed as an exhibit.

       

      As of March 8, 2021, the Company’s authorized capital stock consists of 50,000,000 shares of common stock, par value $0.0001 per share, of which 9,828,000 shares were issued and outstanding. The authorized and unissued shares of common stock are
        available for issuance without further action by the Company’s stockholders, unless such action is required by applicable law or the rules of any stock exchange on which the Company’s securities may be listed. Unless approval of stockholders is so
        required, the Company’s Board of Directors will not seek stockholder approval for the issuance and sale of common stock.

       

      Units

       

      Each unit consists of one share of common stock and three-quarters of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one share of common stock at a price of $11.50 per share, subject to adjustment. Pursuant to
        the warrant agreement, a warrantholder may exercise its warrants only for a whole number of shares of common stock. This means that only a whole warrant may be exercised at any given time by a warrantholder. No fractional warrants will be issued
        upon separation of the units and only whole warrants will trade. Each warrant will become exercisable on the later of one year after the closing of ROCH’s IPO or the consummation of an initial business combination , and will expire five years after
        the completion of an initial business combination, or earlier upon redemption.

       

      The private units held by ROCH’s insiders are identical to the public units described above except that the warrants underlying such private units will be exercisable for cash or on a cashless basis, at the holder’s option, and will not be
        redeemable by us, in each case so long as they are still held by the insiders or their affiliates.

       

      Common Stock

       

      Holders of record of ROCH’s common stock are entitled to one vote for each share held on all matters to be voted on by stockholders. In connection with any vote held to approve ROCH’s initial business combination, ROCH’s insiders, officers and
        directors, have agreed to vote their respective shares of common stock owned by them in favor of the proposed business combination.

       

      
        

        
          

        

      

      
      ROCH will consummate its initial business combination only if public stockholders do not exercise conversion rights in an amount that would cause its net tangible assets to be less than $5,000,001 and if a stockholder vote is held, a majority of
        the outstanding shares of common stock voted are voted in favor of the business combination.

       

      Pursuant to ROCH’s certificate of incorporation, if it does not consummate its initial business combination within 18 months from the closing of its IPO, ROCH will (i) cease all operations except for the purpose of winding up, (ii) as promptly
        as reasonably possible but not more than ten business days thereafter, redeem 100% of the outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further
        liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of any remaining stockholders and its board of directors, dissolve and liquidate, subject
        (in the case of (ii) and (iii) above) to obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. ROCH’s insiders have agreed to waive their rights to share in any distribution with respect to
        their insider shares.

       

      ROCH’s stockholders have no conversion, preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to the shares of common stock, except that public stockholders have the right to sell their shares
        to ROCH in any tender offer or have their shares of common stock converted to cash equal to their pro rata share of the trust account if they vote on the proposed business combination and the business combination is completed. If ROCH holds a
        stockholder vote to amend any provisions of its certificate of incorporation relating to stockholder’s rights or pre-business combination activity (including the substance or timing within which it has to complete a business combination), ROCH will
        provide its public stockholders with the opportunity to redeem their shares of common stock upon approval of any such amendment at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including
        interest earned on the funds held in the trust account and not previously released to ROCH to pay franchise and income taxes, divided by the number of then outstanding public shares, in connection with any such vote. In either of such events,
        converting stockholders would be paid their pro rata portion of the trust account promptly following consummation of the business combination or the approval of the amendment to the certificate of incorporation. If the business combination is not
        consummated or the amendment is not approved, stockholders will not be paid such amounts.

       

      Warrants

       

      Each whole warrant entitles the registered holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment as discussed below, at any time commencing on the later of 12 months from the closing of ROCH’s IPO or
        after the completion of its initial business combination. Pursuant to the warrant agreement, a warrantholder may exercise its warrants only for a whole number of shares of common stock. This means that only a whole warrant may be exercised at any
        given time by a warrantholder. However, no public warrants will be exercisable for cash unless ROCH has an effective and current registration statement covering the shares of common stock issuable upon exercise of the warrants and a current
        prospectus relating to such shares of common stock. Notwithstanding the foregoing, if a registration statement covering the shares of common stock issuable upon exercise of the public warrants is not effective within 120 days from the closing of
        ROCH’s initial business combination, warrant holders may, until such time as there is an effective registration statement and during any period when ROCH shall have failed to maintain an effective registration statement, exercise warrants on a
        cashless basis pursuant to an available exemption from registration under the Securities Act. The warrants will expire five years from the closing of ROCH’s initial business combination at 5:00 p.m., New York City time.

       

      In addition, if (x) ROCH issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial business combination at an issue price or effective issue price of less than
        $9.20 per share (with such issue price or effective issue price to be determined in good faith by its board of directors), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest
        thereon, available for the funding of ROCH’s initial business combination, and (z) the volume weighted average trading price of our shares of common stock during the 20 trading day period starting on the trading day prior to the day on which ROCH
        consummate its initial business combination (such price, the “Market Price”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the Market Price, and the $18.00 per share
        redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 180% of the Market Price.

       

      
        

        2

        
          

        

      

      ROCH may call the outstanding warrants (excluding the warrants underlying the private units held by ROCH’s insiders) for redemption, in whole and not in part, at a price of $.01 per warrant at any time after the warrants become exercisable, upon
        not less than 30 days’ prior written notice of redemption to each warrant holder:

       

      	 	•	
              if, and only if, the reported last sale price of the shares of common stock equals or exceeds $18.00 per share, for any 20 trading days within a 30-day trading period commencing after the warrants become exercisable and ending on the
                third business day prior to the notice of redemption to warrant holders, and

            

      	 	•	
              if, and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing
                each day thereafter until the date of redemption.

            

       

      The right to exercise will be forfeited unless the warrants are exercised prior to the date specified in the notice of redemption. On and after the redemption date, a record holder of a warrant will have no further rights except to receive the
        redemption price for such holder’s warrant upon surrender of such warrant.

       

      The redemption criteria for the warrants have been established at a price which is intended to provide warrant holders a reasonable premium to the initial exercise price and provide a sufficient differential between the then-prevailing share
        price and the warrant exercise price so that if the share price declines as a result of a redemption call, the redemption will not cause the share price to drop below the exercise price of the warrants.

       

      If ROCH calls the warrants for redemption as described above, ROCH management will have the option to require all holders that wish to exercise warrants to do so on a “cashless basis.” In such event, each holder would pay the exercise price by
        surrendering the warrants for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the warrants, multiplied by the difference between the exercise price
        of the warrants and the “fair market value” (defined below) by (y) the fair market value. The “fair market value” for this purpose shall mean the average reported last sale price of the common stock for the 10 trading days ending on the third
        trading day prior to the date on which the notice of redemption is sent to the holders of warrants. Whether ROCH will exercise the option to require all holders to exercise their warrants on a “cashless basis” will depend on a variety of factors
        including the price of the common stock at the time the warrants are called for redemption, ROCH’s cash needs at such time and concerns regarding dilutive share issuances.

       

      The warrants were issued in registered form under a warrant agreement between Continental Stock Transfer & Trust Company, as warrant agent, and ROCH. The warrant agreement provides that the terms of the warrants may be amended without the
        consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval, by written consent or vote, of the holders of a majority of the then outstanding warrants in order to make any change that adversely affects
        the interests of the registered holders.

       

      The exercise price and number of shares of common stock issuable on exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or our recapitalization, reorganization,
        merger or consolidation. However, the warrants will not be adjusted for issuances of shares of common stock at a price below their respective exercise prices.

       

      
        

        3

        
          

        

      

      The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as
        indicated, accompanied by full payment of the exercise price, by certified or official bank check payable to us, for the number of warrants being exercised. The warrant holders do not have the rights or privileges of holders of shares of common
        stock and any voting rights until they exercise their warrants and receive shares of common stock. After the issuance of shares of common stock upon exercise of the warrants, each holder will be entitled to one vote for each share held of record on
        all matters to be voted on by stockholders.

       

      Except as described above, no Public Warrants will be exercisable for cash and ROCH is not obligated to issue shares of common stock unless at the time a holder seeks to exercise such warrant, a prospectus relating to the shares of common stock
        issuable upon exercise of the warrants is current and the shares of common stock have been registered or qualified or deemed to be exempt under the securities laws of the state of residence of the holder of the warrants. Under the terms of the
        warrant agreement, ROCH has agreed to use its best efforts to meet these conditions and to maintain a current prospectus relating to the shares of common stock issuable upon exercise of the warrants until the expiration of the warrants. If the
        prospectus relating to the shares of common stock issuable upon the exercise of the warrants is not current or if the common stock is not qualified or exempt from qualification in the jurisdictions in which the holders of the warrants reside, ROCH
        will not be required to net cash settle or cash settle the warrant exercise, the warrants may have no value, the market for the warrants may be limited and the warrants may expire worthless.

       

      Warrant holders may elect to be subject to a restriction on the exercise of their warrants such that an electing warrant holder would not be able to exercise their warrants to the extent that, after giving effect to such exercise, such holder
        would beneficially own in excess of 9.9% of the shares of common stock outstanding.

       

      No fractional shares will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round down to the nearest whole number the
        number of shares of common stock to be issued to the warrant holder.

       

      As of March 8, 2021, there were 5,936,265 whole warrants outstanding.

       

      Certain Anti-Takeover Effects of Delaware Law and Provisions of ROCH’s Amended and Restated Certificate of Incorporation and Bylaws

       

      ROCH is subject to the provisions of Section 203 of the DGCL regulating corporate takeovers. This statute prevents certain Delaware corporations, under certain circumstances, from engaging in a “business combination”
        with:

       

      	 	•	
              a stockholder who owns 10% or more of our outstanding voting stock (otherwise known as an “interested stockholder”);

            

      

      

      	 	•	
              an affiliate of an interested stockholder; or

            

      

      

      	 	•	
              an associate of an interested stockholder, for three years following the date that the stockholder became an interested stockholder.

            

       

      A “business combination” includes a merger or sale of more than 10% of our assets. However, the above provisions of Section 203 do not apply if:

       

      	 	•	
              the board of directors approves the transaction that made the stockholder an “interested stockholder,” prior to the date of the transaction;

            

      

      

      	 	•	
              after the completion of the transaction that resulted in the stockholder becoming an interested stockholder, that stockholder owned at least 85% of our voting stock outstanding at the time the transaction commenced, other than
                statutorily excluded shares of common stock; or

            

      

      

      	 	•	
              on or subsequent to the date of the transaction, the business combination is approved by the board of directors and authorized at a meeting of stockholders, and not by written consent, by an affirmative vote of at least two-thirds of the
                outstanding voting stock not owned by the interested stockholder.

            

       

      
        

        4

        
          

        

      

      Exclusive Forum For Certain Lawsuits

       

      ROCH’s amended and restated certificate of incorporation requires that derivative actions brought in ROCH’s name, actions against directors, officers and employees for breach of fiduciary duty and other similar actions not including claims that
        arise under the Securities Act or Exchange Act, may be brought only in the Court of Chancery in the State of Delaware. This provision may have the effect of discouraging lawsuits against ROCH’s directors and officers.

       

      Special meeting of stockholders

       

      ROCH’s bylaws provide that special meetings of stockholders may be called only by a majority vote of the board of directors, by the chief executive officer or by the chairman.

       

      Advance notice requirements for stockholder proposals and director nominations

       

      ROCH’s bylaws provide that stockholders seeking to bring business before an annual meeting of stockholders, or to nominate candidates for election as directors at an annual meeting of stockholders must provide timely
        notice of their intent in writing. To be timely, a stockholder’s notice will need to be delivered to ROCH’s principal executive offices not later than the close of business on the 90th day nor earlier than the opening of business on the 120th day
        prior to the scheduled date of the annual meeting of stockholders. ROCH’s bylaws also specify certain requirements as to the form and content of a stockholders’ meeting. These provisions may preclude our stockholders from bringing matters before an
        annual meeting of stockholders or from making nominations for directors at an annual meeting of stockholders.

       

      Authorized but unissued shares

       

      ROCH’s authorized but unissued common stock is available for future issuances without stockholder approval and could be utilized for a variety of corporate purposes, including future offerings to raise additional
        capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock could render more difficult or discourage an attempt to obtain control of ROCH by means of a proxy contest, tender offer, merger
        or otherwise.

       

      

       

      

      5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]